An Z, Wang J, Li C, Tang C
Cell Commun Signal. 2025; 23(1):25.
PMID: 39806388
PMC: 11730785.
DOI: 10.1186/s12964-024-02005-x.
Abou-Jaoude A, Huang C, Flores J, Ravichandran M, Lei R, Chrysanthou S
Stem Cell Res. 2022; 61:102770.
PMID: 35390758
PMC: 10810145.
DOI: 10.1016/j.scr.2022.102770.
Ayaz G, Turan G, Olgun C, Kars G, Karakaya B, Yavuz K
Sci Rep. 2021; 11(1):17587.
PMID: 34475492
PMC: 8413330.
DOI: 10.1038/s41598-021-97060-6.
Yasar P, Kars G, Yavuz K, Ayaz G, Oguztuzun C, Bilgen E
Sci Rep. 2021; 11(1):15655.
PMID: 34341443
PMC: 8329181.
DOI: 10.1038/s41598-021-95165-6.
Astori A, Matherat G, Munoz I, Gautier E, Surdez D, Zermati Y
Haematologica. 2020; 107(1):268-283.
PMID: 33241676
PMC: 8719099.
DOI: 10.3324/haematol.2020.263558.
The KN Motif and Ankyrin Repeat Domains 1/CXXC Finger Protein 5 Axis Regulates Epithelial-Mesenchymal Transformation, Metastasis and Apoptosis of Gastric Cancer via Wnt Signaling.
Chen X, Wang X, Yi L, Song Y
Onco Targets Ther. 2020; 13:7343-7352.
PMID: 32801759
PMC: 7395690.
DOI: 10.2147/OTT.S240991.
CXXC5 as an unmethylated CpG dinucleotide binding protein contributes to estrogen-mediated cellular proliferation.
Ayaz G, Razizadeh N, Yasar P, Kars G, Kahraman D, Saatci O
Sci Rep. 2020; 10(1):5971.
PMID: 32249801
PMC: 7136269.
DOI: 10.1038/s41598-020-62912-0.
CXXC5 Mediates -suppressed Cementoblast Functions Partially via MAPK Signaling Network.
Ma L, Wang X, Liu H, Jiang C, Liao H, Xu S
Int J Biol Sci. 2019; 15(8):1685-1695.
PMID: 31360111
PMC: 6643218.
DOI: 10.7150/ijbs.35419.
CXXC5: A novel regulator and coordinator of TGF-β, BMP and Wnt signaling.
Xiong X, Tu S, Wang J, Luo S, Yan X
J Cell Mol Med. 2018; 23(2):740-749.
PMID: 30479059
PMC: 6349197.
DOI: 10.1111/jcmm.14046.
Overexpression of CXXC5 is a strong poor prognostic factor in ER+ breast cancer.
Fang L, Wang Y, Gao Y, Chen X
Oncol Lett. 2018; 16(1):395-401.
PMID: 29928427
PMC: 6006432.
DOI: 10.3892/ol.2018.8647.
CXXC5 expression in prostate cancer: implications for cancer progression.
Benedetti I, De Marzo A, Geliebter J, Reyes N
Int J Exp Pathol. 2017; 98(4):234-243.
PMID: 29027288
PMC: 5639265.
DOI: 10.1111/iep.12241.
Epigenetic regulator CXXC5 recruits DNA demethylase Tet2 to regulate TLR7/9-elicited IFN response in pDCs.
Ma S, Wan X, Deng Z, Shi L, Hao C, Zhou Z
J Exp Med. 2017; 214(5):1471-1491.
PMID: 28416650
PMC: 5413332.
DOI: 10.1084/jem.20161149.
KANK1 inhibits cell growth by inducing apoptosis through regulating CXXC5 in human malignant peripheral nerve sheath tumors.
Cui Z, Shen Y, Chen K, Mittal S, Yang J, Zhang G
Sci Rep. 2017; 7:40325.
PMID: 28067315
PMC: 5220314.
DOI: 10.1038/srep40325.
Estradiol-Estrogen Receptor α Mediates the Expression of the CXXC5 Gene through the Estrogen Response Element-Dependent Signaling Pathway.
Yasar P, Ayaz G, Muyan M
Sci Rep. 2016; 6:37808.
PMID: 27886276
PMC: 5122896.
DOI: 10.1038/srep37808.
Length of paternal lifespan is manifested in the DNA methylome of their nonagenarian progeny.
Marttila S, Kananen L, Jylhava J, Nevalainen T, Hervonen A, Jylha M
Oncotarget. 2015; 6(31):30557-67.
PMID: 26436701
PMC: 4741551.
DOI: 10.18632/oncotarget.5905.
Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.
Kuhnl A, Valk P, Sanders M, Ivey A, Hills R, Mills K
Blood. 2015; 125(19):2985-94.
PMID: 25805812
PMC: 4463809.
DOI: 10.1182/blood-2014-12-613703.
CXXC5 is a negative-feedback regulator of the Wnt/β-catenin pathway involved in osteoblast differentiation.
Kim H, Yoon J, Yun J, Cho K, Lee S, Rhee Y
Cell Death Differ. 2015; 22(6):912-20.
PMID: 25633194
PMC: 4423189.
DOI: 10.1038/cdd.2014.238.
Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation.
Bruserud O, Reikvam H, Fredly H, Skavland J, Hagen K, van Hoang T
Oncotarget. 2015; 6(5):2794-811.
PMID: 25605239
PMC: 4413618.
DOI: 10.18632/oncotarget.3056.
The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.
Solary E, Bernard O, Tefferi A, Fuks F, Vainchenker W
Leukemia. 2013; 28(3):485-96.
PMID: 24220273
DOI: 10.1038/leu.2013.337.
CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia.
Astori A, Fredly H, Aloysius T, Bullinger L, Mas V, De La Grange P
Oncotarget. 2013; 4(9):1438-48.
PMID: 23988457
PMC: 3824541.
DOI: 10.18632/oncotarget.1195.